Atara Biotherapeutics, Inc.
ATRA
Price:
$9.47
Market Cap:
$46.55M
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 for B-cell malignancies, as well as ATA188 for the treatment of...[Read more]
Industry
Biotechnology
IPO Date
2014-10-16
Stock Exchange
NASDAQ
Ticker
ATRA
The ROE as of September 2024 (TTM) for Atara Biotherapeutics, Inc. (ATRA) is 2.02%
According to Atara Biotherapeutics, Inc.’s latest financial reports and current stock price. The company's current ROE is 2.02%. This represents a change of 225.55% compared to the average of 619.23% of the last 4 quarters.
Atara Biotherapeutics, Inc. (ATRA) Historical ROE (quarterly & annually)
How has ATRA ROE performed in the past?
The mean historical ROE of Atara Biotherapeutics, Inc. over the last ten years is -401.76%. The current 2.02% ROE has changed -601.76% with respect to the historical average. Over the past ten years (40 quarters), ATRA's ROE was at its highest in in the September 2023 quarter at 1.37%. The ROE was at its lowest in in the June 2023 quarter at -9539.58%.
Average
-401.76%
Median
-667.50%
Minimum
-1802.76%
Maximum
2.78%
Atara Biotherapeutics, Inc. (ATRA) ROE by Quarter and Year
Discovering the peaks and valleys of Atara Biotherapeutics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 115.64%
Maximum Annual ROE = 2.78%
Minimum Annual Increase = -254.36%
Minimum Annual ROE = -1802.76%
| Year | ROE | Change |
|---|---|---|
| 2023 | 2.78% | -254.36% |
| 2022 | -1802.76% | 48.20% |
| 2021 | -1216.47% | 83.43% |
| 2020 | -663.19% | -33.73% |
| 2019 | -1000.67% | 46.98% |
| 2018 | -680.82% | 1.34% |
| 2017 | -671.81% | 115.64% |
| 2016 | -311.54% | 71.56% |
| 2015 | -181.60% | -33.09% |
| 2014 | -271.42% | -134.08% |
Atara Biotherapeutics, Inc. (ATRA) Average ROE
How has ATRA ROE performed in the past?
The current ROE of Atara Biotherapeutics, Inc. (ATRA) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-78.86%
5-year avg
-380.09%
10-year avg
-401.76%
Atara Biotherapeutics, Inc. (ATRA) ROE vs. Peers
How is ATRA’s ROE compared to its peers?
Atara Biotherapeutics, Inc.’s ROE is greater than Fate Therapeutics, Inc. (-44.09%), greater than Sana Biotechnology, Inc. (-71.60%), greater than Caribou Biosciences, Inc. (-34.76%), greater than Arcus Biosciences, Inc. (-42.86%), less than Heron Therapeutics, Inc. (144.24%), greater than Allogene Therapeutics, Inc. (-53.76%), less than BioXcel Therapeutics, Inc. (176.93%), less than Karyopharm Therapeutics Inc. (66.89%), less than X4 Pharmaceuticals, Inc. (32.93%), greater than HOOKIPA Pharma Inc. (-51.77%), greater than Mereo BioPharma Group plc (-63.39%), less than Galera Therapeutics, Inc. (21.95%), greater than Acumen Pharmaceuticals, Inc. (-24.63%), greater than VectivBio Holding AG (-56.92%), greater than Icosavax, Inc. (-41.24%), greater than Apellis Pharmaceuticals, Inc. (-139.02%), greater than iTeos Therapeutics, Inc. (-18.19%), greater than TScan Therapeutics, Inc. (-59.83%),
| Company | ROE | Market cap |
|---|---|---|
| -44.09% | $386.05M | |
| -71.60% | $1.12B | |
| -34.76% | $155.42M | |
| -42.86% | $1.44B | |
| 144.24% | $273.00M | |
| -53.76% | $503.96M | |
| 176.93% | $22.26M | |
| 66.89% | $91.04M | |
| 32.93% | $109.78M | |
| -51.77% | $159.50M | |
| -63.39% | $664.26M | |
| 21.95% | $4.08M | |
| -24.63% | $133.38M | |
| -56.92% | $1.06B | |
| -41.24% | $769.04M | |
| -139.02% | $5.00B | |
| -18.19% | $540.52M | |
| -59.83% | $294.00M |
Build a custom stock screener for Atara Biotherapeutics, Inc. (ATRA) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Atara Biotherapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Atara Biotherapeutics, Inc. (ATRA) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Atara Biotherapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Atara Biotherapeutics, Inc.'s ROE?
How is the ROE calculated for Atara Biotherapeutics, Inc. (ATRA)?
What is the highest ROE for Atara Biotherapeutics, Inc. (ATRA)?
What is the 3-year average ROE for Atara Biotherapeutics, Inc. (ATRA)?
What is the 5-year average ROE for Atara Biotherapeutics, Inc. (ATRA)?
How does the current ROE for Atara Biotherapeutics, Inc. (ATRA) compare to its historical average?